Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia

Arthur E. Frankel, Michael W. Schuster, Joseph G. Jurcic

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Patients with chemotherapy-resistant acute myeloid leukaemia are rarely cured by non-allogeneic transplant therapies. Multiple new investigational agents have become available for treatment of these patients and there are few tools to permit rational drug and clinical trial selection. In this review, we describe the chemical and biological properties of some of these agents and some of their initial clinical activity to date. The selected agents react with either cell surface molecules or signal pathway intermediates and include antibody and antibody conjugates to CD33 and CD45. a fusion protein directed to the granulocyte-macrophage colony-stimulating factor receptor, an anti-sense oligonucleotide to Bcl2. a farnesyl transferase inhibitor, and a protein kinase C agonist/inhibitor. The challenge for the next decade will be how to select patients for particular molecularly targeted therapeutics and how to combine these agents.

Original languageEnglish (US)
Pages (from-to)55-71
Number of pages17
JournalBioDrugs
Volume15
Issue number1
StatePublished - 2001

Fingerprint

Acute Myeloid Leukemia
Drug Therapy
Granulocyte-Macrophage Colony-Stimulating Factor Receptors
Antibodies
Antisense Oligonucleotides
Transferases
Protein Kinase C
Signal Transduction
Therapeutics
Clinical Trials
Transplants
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Immunology and Allergy
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Frankel, A. E., Schuster, M. W., & Jurcic, J. G. (2001). Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia. BioDrugs, 15(1), 55-71.

Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia. / Frankel, Arthur E.; Schuster, Michael W.; Jurcic, Joseph G.

In: BioDrugs, Vol. 15, No. 1, 2001, p. 55-71.

Research output: Contribution to journalArticle

Frankel, AE, Schuster, MW & Jurcic, JG 2001, 'Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia', BioDrugs, vol. 15, no. 1, pp. 55-71.
Frankel, Arthur E. ; Schuster, Michael W. ; Jurcic, Joseph G. / Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia. In: BioDrugs. 2001 ; Vol. 15, No. 1. pp. 55-71.
@article{651ca6a5d740449b90ebb4ee16e0779a,
title = "Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia",
abstract = "Patients with chemotherapy-resistant acute myeloid leukaemia are rarely cured by non-allogeneic transplant therapies. Multiple new investigational agents have become available for treatment of these patients and there are few tools to permit rational drug and clinical trial selection. In this review, we describe the chemical and biological properties of some of these agents and some of their initial clinical activity to date. The selected agents react with either cell surface molecules or signal pathway intermediates and include antibody and antibody conjugates to CD33 and CD45. a fusion protein directed to the granulocyte-macrophage colony-stimulating factor receptor, an anti-sense oligonucleotide to Bcl2. a farnesyl transferase inhibitor, and a protein kinase C agonist/inhibitor. The challenge for the next decade will be how to select patients for particular molecularly targeted therapeutics and how to combine these agents.",
author = "Frankel, {Arthur E.} and Schuster, {Michael W.} and Jurcic, {Joseph G.}",
year = "2001",
language = "English (US)",
volume = "15",
pages = "55--71",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia

AU - Frankel, Arthur E.

AU - Schuster, Michael W.

AU - Jurcic, Joseph G.

PY - 2001

Y1 - 2001

N2 - Patients with chemotherapy-resistant acute myeloid leukaemia are rarely cured by non-allogeneic transplant therapies. Multiple new investigational agents have become available for treatment of these patients and there are few tools to permit rational drug and clinical trial selection. In this review, we describe the chemical and biological properties of some of these agents and some of their initial clinical activity to date. The selected agents react with either cell surface molecules or signal pathway intermediates and include antibody and antibody conjugates to CD33 and CD45. a fusion protein directed to the granulocyte-macrophage colony-stimulating factor receptor, an anti-sense oligonucleotide to Bcl2. a farnesyl transferase inhibitor, and a protein kinase C agonist/inhibitor. The challenge for the next decade will be how to select patients for particular molecularly targeted therapeutics and how to combine these agents.

AB - Patients with chemotherapy-resistant acute myeloid leukaemia are rarely cured by non-allogeneic transplant therapies. Multiple new investigational agents have become available for treatment of these patients and there are few tools to permit rational drug and clinical trial selection. In this review, we describe the chemical and biological properties of some of these agents and some of their initial clinical activity to date. The selected agents react with either cell surface molecules or signal pathway intermediates and include antibody and antibody conjugates to CD33 and CD45. a fusion protein directed to the granulocyte-macrophage colony-stimulating factor receptor, an anti-sense oligonucleotide to Bcl2. a farnesyl transferase inhibitor, and a protein kinase C agonist/inhibitor. The challenge for the next decade will be how to select patients for particular molecularly targeted therapeutics and how to combine these agents.

UR - http://www.scopus.com/inward/record.url?scp=0035115650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035115650&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 55

EP - 71

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 1

ER -